1-(4-Nitrophenyl)piperidine is a synthetic compound that has been investigated for its potential pharmacological properties. It is a piperidine derivative with a nitro group attached to the phenyl ring at the para position. The synthesis of this compound typically involves the reaction of 4-nitroaniline with piperidine. Research on 1-(4-nitrophenyl)piperidine has focused on its potential as a ligand for certain receptors in the central nervous system, particularly serotonin receptors. Studies have shown that it exhibits affinity for these receptors, suggesting potential therapeutic applications related to mood disorders and anxiety. However, further research is needed to fully understand its pharmacological profile and potential side effects before it can be considered for clinical use. The compound is studied to gain insights into the structure-activity relationships of serotonin receptor ligands and to explore its potential as a drug candidate.'
| ID Source | ID |
|---|---|
| PubMed CID | 81049 |
| CHEMBL ID | 1370351 |
| CHEBI ID | 192636 |
| SCHEMBL ID | 223626 |
| Synonym |
|---|
| AC-7241 |
| einecs 229-492-7 |
| ai3-02748 |
| frz5eyh8v6 , |
| unii-frz5eyh8v6 |
| nsc 15441 |
| piperidine, 1-(4-nitrophenyl)- |
| nsc15441 |
| nsc-15441 |
| 6574-15-8 |
| 1-(p-nitrophenyl)piperidine |
| 1-(4-nitrophenyl)piperidine |
| OPREA1_814030 |
| MLS001049200 , |
| smr000427734 |
| 1-(4-nitro-phenyl)-piperidine |
| MAYBRIDGE1_000682 |
| STK124276 |
| inchi=1/c11h14n2o2/c14-13(15)11-6-4-10(5-7-11)12-8-2-1-3-9-12/h4-7h,1-3,8-9h2 |
| sgplaxfudtwhrs-uhfffaoysa- |
| HMS543G22 |
| CHEBI:192636 |
| AKOS001044830 |
| HMS2812O10 |
| NCGC00246353-01 |
| n-(p-nitrophenyl)piperidine |
| FT-0605771 |
| SCHEMBL223626 |
| SY005308 |
| mfcd00023662 |
| n-(4-nitrophenyl)piperidine |
| 4-(piperidin-1-yl)-1-nitrobenzene |
| DS-0183 |
| bdbm56752 |
| cid_81049 |
| CHEMBL1370351 |
| DTXSID70215942 |
| SR-01000390071-1 |
| sr-01000390071 |
| Z31192699 |
| CS-0206411 |
| 1-(4-nitrophenyl)piperidine 6574-15-8 |
| AMY860 |
| p-nitropiperidinobenzene |
| piperidine, 1-(p-nitrophenyl)- |
| p-(1-piperidinyl)nitrobenzene |
| 4-piperidinonitrobenzene |
| SB43358 |
| Class | Description |
|---|---|
| piperidines | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 37.9330 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 29.0810 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 8.9125 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 84.9214 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 100.0000 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| geminin | Homo sapiens (human) | Potency | 6.5131 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 28.1838 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| kallikrein-5 preproprotein | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 1.3592 | 11.3060 | 50.0000 | AID1431 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| protein PvdQ | Pseudomonas aeruginosa LESB58 | AC50 | 6.5160 | 3.9810 | 23.3263 | 80.9600 | AID493231 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.94) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||